• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bigfoot Biomedical

SFC Fluidics inks deal with JDRF to develop automated insulin delivery system

January 22, 2018 By Sarah Faulkner

SFC Fluidics

SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Bigfoot Biomedical, Juvenile Diabetes Research Foundation (JDRF), Medtronic, sfcfluidics

Bigfoot Biomedical raises $37m in Series B

December 18, 2017 By Sarah Faulkner

Bigfoot Biomedical

Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor, Quadrant Capital Advisors. The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Abbott Laboratories, Bigfoot Biomedical

Bigfoot Biomedical CEO hits back against CMS over data-sharing decision

November 15, 2017 By Sarah Faulkner

Bigfoot Biomedical

Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it would begin covering the use of particular continuous glucose monitors for people with diabetes. But since that decision, the agency has […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Bigfoot Biomedical, DexCom Inc.

Bigfoot compares trial data with modeling results for automated insulin delivery system

November 7, 2017 By Sarah Faulkner

Bigfoot Biomedical automated insulin delivery system

Bigfoot Biomedical touted data last week at this year’s Diabetes Technology Meeting showing that results from a feasibility study evaluating the company’s automated insulin delivery system closely matched data gleaned from prospective modeling. The company said it conducted extensive modeling to refine the technology’s algorithms prior to the start of its trial in 2016, Bigfoot […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Bigfoot Biomedical

Ypsomed to supply Bigfoot with insulin infusion sets for pivotal trial

October 24, 2017 By Sarah Faulkner

Bigfoot, Ypsomed

Ypsomed plans to supply Bigfoot Biomedical with a modified version of its Orbit infusion set for the pivotal trial of Bigfoot’s automated insulin delivery system, the companies said today. Ypsomed’s Orbit infusion sets can be rotated 360°, giving users the freedom to move around, and are fitted using a heat-activated patch. The infusion sets are available with steel or […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Bigfoot Biomedical, Ypsomed

Here’s how the diabetes industry’s leaders think about patient-centered R&D

October 11, 2017 By Sarah Faulkner

diabetes

Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday lives. Underscoring those products is often years of research and some in the industry have begun to think about how a patient’s needs […]

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Bigfoot Biomedical, drugstars, Eli Lilly & Co., Novo Nordisk

Why Bigfoot Biomedical’s CEO thinks the diabetes industry has a data problem

September 29, 2017 By Sarah Faulkner

Bigfoot Biomedical

Bigfoot Biomedical‘s chief executive is excited about Abbott‘s (NYSE:ABT) latest regulatory win – and it’s not just because the two companies have an established partnership. Yesterday, the FDA approved Abbott’s FreeStyle Libre Flash continuous glucose monitoring system. It’s the first device of its kind, allowing patients to track their blood glucose levels without the use […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Bigfoot Biomedical, DeviceTalks West, DexCom Inc.

Convenience, compliance & control: How Insulet is changing insulin delivery tech

September 21, 2017 By Sarah Faulkner

Insulet Omnipod

Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other challenges that come with constantly wearing a pump. So when Petrovic was tapped to serve as chief commercial officer at Insulet (NSDQ:PODD) in […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Bigfoot Biomedical, Eli Lilly & Co., GlaxoSmithKline plc, Insulet, Medtronic, Ypsomed

Biotech, pharma chime in over Trump’s move to halt immigration program

September 6, 2017 By Sarah Faulkner

capitol hill

On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in the U.S. as children. Attorney general Jeff Sessions said Tuesday morning that Trump would move to halt the Deferred Action for Childhood Arrivals program in six months, unless […]

Filed Under: Featured, Legal News, Wall Street Beat Tagged With: Acorda Therapeutics, Alnylam Pharmaceuticals, Bigfoot Biomedical, Biogen Idec, decibeltherapeutics, junotherapeutics, ovidtherapeutics

Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment

July 21, 2017 By Sarah Faulkner

Abbott

Just one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White told analysts that he thinks Bigfoot is playing an important role in the strategic change taking place in the space. “It’s a fairly clever service and approach that I think will create, not just an […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Bigfoot Biomedical

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS